Dr. Melissa Johnson, MD
Claim this profileSarah Cannon Research Institute
Expert in Lung Cancer
Expert in Solid Tumors
66 reported clinical trials
94 drugs studied
About Melissa Johnson, MD
Education:
- Awarded the Morehead-Cain Scholarship at the University of North Carolina, Chapel Hill.
- Obtained an MD (Doctor of Medicine) from the University of Pennsylvania.
Experience:
- Served as Chief Fellow for one year at an unspecified institution.
- Co-founded the Northwestern Medical Developmental Therapeutics Institute.
- Since 2014, has been with the Sarah Cannon Research Institute at Tennessee Oncology, now the Associate Director of Lung Cancer Research.
- Focuses on expanding phase II and III lung cancer clinical trials and developing early-phase compounds for thoracic cancers.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Solid Tumors
Global LeaderStage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Melissa Johnson, MD is currently running
PC14586
for Solid Tumors
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Recruiting1 award Phase 1 & 25 criteria
Osimertinib + Chemotherapy
for Lung Cancer
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Recruiting1 award Phase 29 criteria
More about Melissa Johnson, MD
Clinical Trial Related6 years of experience running clinical trials · Led 66 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Melissa Johnson, MD has experience with
- Pembrolizumab
- Atezolizumab
- Docetaxel
- Carboplatin
- Nivolumab
- Osimertinib
Breakdown of trials Melissa Johnson, MD has run
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer
- Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Solid Tumors
Non-Small Cell Lung Cancer
Pancreatic Cancer
Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Engineered T-Cell Therapy for Advanced Cancer
- ZW171 for Mesothelioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Melissa Johnson, MD specialize in?
Melissa Johnson, MD focuses on Lung Cancer and Solid Tumors. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Melissa Johnson, MD currently recruiting for clinical trials?
Yes, Melissa Johnson, MD is currently recruiting for 18 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Melissa Johnson, MD has studied deeply?
Yes, Melissa Johnson, MD has studied treatments such as Pembrolizumab, Atezolizumab, Docetaxel.
What is the best way to schedule an appointment with Melissa Johnson, MD?
Apply for one of the trials that Melissa Johnson, MD is conducting.
What is the office address of Melissa Johnson, MD?
The office of Melissa Johnson, MD is located at: Sarah Cannon Research Institute, Nashville, Tennessee 37221 United States. This is the address for their practice at the Sarah Cannon Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.